Epidemiology of metabolic risk factors in Uganda

Lead Research Organisation: University of Cambridge
Department Name: Institute of Public Health

Abstract

Non-communicable diseases (NCDs), such as type 2 diabetes and heart disease, are emerging as major health problems in sub-Saharan Africa, including Uganda. To help inform future prevention and treatment for NCDs in these populations, it will be important to identify and understand the risk factors that may influence the development of NCDs in African populations. The overall aim of the study is to assess the patterns and distributions of these risk factors, and their interrelation with infectious factors, in Ugandan populations. Our objectives are to characterise the variation in circulating blood risk factors such as cholesterol, glucose, genetic markers and obesity in up to 15,000 people from urban and rural areas of Uganda.

The study will help provide a greater understanding of diseases in African populations, informing potential therapies. Importantly, the study will provide estimates of the prevalence of NCDs, such as type 2 diabetes. This information will provide the the basis for health policy and public health programmes aimed at addressing the rise of NCDs in Uganda. It may also inform public health strategies in other African countries.

Technical Summary

Non-communicable diseases (NCDs) are emerging as a major health problem in sub-Saharan Africa. Currently, one of the major obstacles in developing appropriate preventative strategies at the national level is a lack of reliable data on disease burden and associated risk factors. The overall aim of the proposal is to assess the epidemiology of metabolic risk factors, and their interrelation with infectious factors, in Ugandan populations.

We will measure metabolic biomarkers and infectious factors in up to 10,000 participants from the General Population Cohort (GPC) study, a rural population-based cohort of around 18,000 people who are followed up annually through demographic socio-medical and serological surveys. Measurements of anthropometric factors and blood pressure will be done as part of the usual survey rounds for the GPC study. We will also measure selected metabolic risk factors in up to 5,000 participants from a national cross sectional study that is broadly representative of the Ugandan population?the AIDS Indicator Survey 2004/2005. This approach will provide the opportunity to compare potential differences between urban and rural study participants for the distribution and prevalence of metabolic risk factors. Given the marked differences in metabolic risk factors among ethnic groups, and using customised genome-wide chip arrays, we will also use genetic epidemiological approaches to provide greater insight into the biological mechanisms underlying the variation in metabolic risk factors in African populations.

This proposal will help provide a unique framework to build on a large scale prospective cohort study to examine a wide range of health indices in an African population?providing the groundwork for long-term study. It will also provide potential aetiological insights into potential determinants of the variation in metabolic and infectious risk factors using both population genetic and epidemiological approaches; estimates of the prevalence of metabolic disorders (T2D, dyslipidaemia and liver dysfunction) in these populations; and the basis for health policy and public health programmes aimed at addressing the rise of NCDs in Uganda, which may also inform public health strategies in other African countries.

Organisations

Publications

10 25 50

publication icon
Barr A (2016) The need for an integrated approach for chronic disease research and care in Africa in Global Health, Epidemiology and Genomics

publication icon
Heckerman D (2016) Linear mixed model for heritability estimation that explicitly addresses environmental variation. in Proceedings of the National Academy of Sciences of the United States of America

 
Description Medical bioinformatics strategic award
Amount £2,830,000 (GBP)
Funding ID MR/L016273/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 01/2014 
End 12/2018
 
Description Network of Excellence
Amount £180,000 (GBP)
Funding ID 260694 
Organisation European Commission 
Department Seventh Framework Programme (FP7)
Sector Public
Country European Union (EU)
Start 11/2012 
End 11/2015
 
Description Wellcome Trust H3Africa
Amount £2,550,000 (GBP)
Funding ID 060743 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 01/2013 
End 12/2017
 
Description Wellcome Trust Sanger Institute core funding
Amount £750,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2011 
End 10/2012
 
Title E-questionnaire 
Description We have developed software (EQ) to electronically capture questionnaire data in the field using a tablet or a laptop computer. Electronic data capture devices may lower the cost and time of study monitoring and data management, as well as reduce the amount of data cleaning necessary upon return from the field. It is anticipated that the EQ will become the template for harmonised and standardised data collection for various research activities across Sub-Saharan Africa. 
Type Of Material Improvements to research infrastructure 
Year Produced 2012 
Provided To Others? Yes  
Impact It is too early to measure the impact. 
 
Title Sequencing data on human genomes 
Description As part of an analysis to identify high frequency genetic variants at the population level, we have sequenced whole genomes at low and high coverage from sub-Saharan Africa and South Asia. These data will be publicly available through managed databases. 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact The sequencing data will be publicly available to the scientific community. 
 
Title Ugandan Medical Informatics Centre (UMIC) 
Description The Ugandan Medical Informatics Centre (UMIC) provides a high end computational resource for studies all over Africa which will require big data analysis and storage. 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact - Provision of trainings on medical informatic techniques for African students. - Integration and curation of large data sets originated from population studies within the continent. - Computational resources available to APCDR partners to conduct genomic and population studies. - Building the capacity of Ugandan Bioinformaticians through collaborative skills sharing and training, enabling local Bioinformaticians to take leading roles in the operations of the data centre. 
 
Title Ugandan NCD cohort study 
Description Biological samples and data on more than 8,000 Ugandans, including next generation genotyping and sequencing data. 
Type Of Material Database/Collection of Data/Biological Samples 
Year Produced 2011 
Provided To Others? Yes  
Impact The genomic data have been made publicly available along with relevant clinical phenotypes. 
 
Title AGR - ADRP 
Description The overarching theme of the African Genomic Resources (AGR) project is to design and create resources to support medical genetic studies in Africa. Whole genome sequencing projects such as HapMap, 1000 Genomes, UK10K and Genomes of the Netherlands have allowed the generation of large and diverse haplotype reference panels for humans. In spite of these efforts, sequences available from populations within Africa have been limited, and are not representative of the genetic diversity across the continent. Recent efforts such as the African Genome Variation Project (AGVP), Ethiopian diversity panels and UG2G (Uganda 2000) have greatly expanded on these resources, producing the largest panels of sequence data from Africa to date. The African Diversity Reference Panel (ADRP) integrates all of these resources with additional sequences from diverse populations across Africa, with the aim of providing a continent-specific reference panel as a resource for medical genetics in Africa and globally. This panel will provide the largest resource of diverse haplotypes across Africa to date, contributing to initiatives such as the Haplotype Consortium, accessible to researchers worldwide. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? Yes  
Impact We envisage that this panel of diverse populations across Africa will increase imputation accuracy across the allele frequency spectrum, and improve the statistical power for any SNP array based GWAS carried out in Africa. This panel will additionally inform efforts to design efficient continent specific SNP arrays, with better coverage across African populations. 
URL https://imputation.sanger.ac.uk/?about=1
 
Title African Genome Variation (AGV) 
Description The AGV data includes dense genotypes from 1,481 and whole genome sequences (WGS) from 320 individuals across SSA. 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact The African Genome Variation (AGV) data provides a resource to help design, implement and interpret genomic studies in sub-Saharan Africa (SSA) and worldwide. Given the marked genetic diversity across populations across SSA, the use of reference imputation panels from SSA populations for other SSA populations, may improve imputation accuracy compared with other population groups we therefore used sequence data to generate an African reference panel for imputation. This will serve as a resource in addition to existing panels. 
URL https://www.ebi.ac.uk/ega/home
 
Title ug2g 
Description whole genome sequences for 2,000 Ugandan individuals 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact The data will be made available to the research community through public databases (e.g. EGA). 
 
Description African Genome Variation (AGV) 
Organisation Addis Ababa University
Country Ethiopia, Federal Democratic Republic of 
Sector Academic/University 
PI Contribution This work aims to facilitate large-scale genetic association studies in diseases of relevance to SSA populations by providing first insights into the genetic variation landscape of different ethnic groups across SSA. My research team genotyped 100 unrelated individuals from each of several ethnic or ethno-linguistic groups on the 2.5 million SNP Illumina HumanOmni chip. To corroborate our analyses we also included whole genome sequences for three of these groups. This work will inform genomic epidemiological studies in SSA by providing a reference for allelic, haplotype and linkage disequilibrium (LD) structure for common variants in populations not covered by the HapMap project. This project has been designed to provide a currently unavailable genome-wide view of common variation and a framework for statistically imputing genetic variants for genome wide association studies in anticipation of future larger-scale whole-genome sequencing endeavours in relevant populations.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa provided existing (biobanked) sample collections with appropriate research ethics consent. Most of these partners were also directly involved in the analyses of the resulting data.
Impact The overarching aim of this project was to characterise common (minor allele frequency > 5 percent) sequence variation in SSA populations in order to facilitate the design of powerful genetic association studies. Specifically, we will aim to: 1) examine the allele frequency spectrum of variants on the chip; 2) characterise patterns of LD and haplotype structure; 3) evaluate optimal study designs for African genomics; 4) investigate imputation-based approaches aiming to increase genetic association study power; 5) identify analytical challenges and develop statistical genetics methods to address them; 6) generate a valuable resource for the scientific community; 7) promote collaboration and synergies among contributing parties; and 8) provide a research framework and resource for additional analyses, for example studies of genome-wide selection, mapping genetic variation to linguistic and demographic differences, and evaluating powerful approaches for trans-ethnic meta-analysis and fine-mapping. The first manuscript has been accepted for publication: Deepti Gurdasani , †, Tommy Carstensen1,2†, Fasil Tekola-Ayele †, Luca Pagani1†, Ioanna Tachmazidou1†, Konstantinos Hatzikotoulas1, Savita Karthikeyan1,2, Louise Iles1,2, Martin O. Pollard1, Ananyo Choudhury , Graham R. S. Ritchie1, , Yali Xue1, Jennifer Asimit1, Rebecca N. Nsubuga , Elizabeth H. Young1,2, Cristina Pomilla1,2, Katja Kivinen1, Kirk Rockett , Anatoli Kamali6, Ayo P. Doumatey3, Gershim Asiki6, Janet Seeley6, Fatoumatta Sisay-Joof , Muminatou Jallow8, Stephen Tollman4, , Ephrem Mekonnen , Rosemary Ekong , Tamiru Oljira10, Neil Bradman , Kalifa Bojang8, Michele Ramsay4, Adebowale Adeyemo3, Endashaw Bekele10, Ayesha Motala , Shane A. Norris4, Fraser Pirie13, Pontiano Kaleebu6, Dominic Kwiatkowski1, Chris Tyler-Smith1‡, Charles Rotimi3‡, Eleftheria Zeggini1‡ and Manjinder S. Sandhu1,2‡. (In press) The African Genome Variation Project shapes medical genetics in Africa. Nature
Start Year 2011
 
Description African Genome Variation (AGV) 
Organisation MRC/UVRI Uganda Research Unit on AIDS
Country Uganda, Republic of 
Sector Public 
PI Contribution This work aims to facilitate large-scale genetic association studies in diseases of relevance to SSA populations by providing first insights into the genetic variation landscape of different ethnic groups across SSA. My research team genotyped 100 unrelated individuals from each of several ethnic or ethno-linguistic groups on the 2.5 million SNP Illumina HumanOmni chip. To corroborate our analyses we also included whole genome sequences for three of these groups. This work will inform genomic epidemiological studies in SSA by providing a reference for allelic, haplotype and linkage disequilibrium (LD) structure for common variants in populations not covered by the HapMap project. This project has been designed to provide a currently unavailable genome-wide view of common variation and a framework for statistically imputing genetic variants for genome wide association studies in anticipation of future larger-scale whole-genome sequencing endeavours in relevant populations.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa provided existing (biobanked) sample collections with appropriate research ethics consent. Most of these partners were also directly involved in the analyses of the resulting data.
Impact The overarching aim of this project was to characterise common (minor allele frequency > 5 percent) sequence variation in SSA populations in order to facilitate the design of powerful genetic association studies. Specifically, we will aim to: 1) examine the allele frequency spectrum of variants on the chip; 2) characterise patterns of LD and haplotype structure; 3) evaluate optimal study designs for African genomics; 4) investigate imputation-based approaches aiming to increase genetic association study power; 5) identify analytical challenges and develop statistical genetics methods to address them; 6) generate a valuable resource for the scientific community; 7) promote collaboration and synergies among contributing parties; and 8) provide a research framework and resource for additional analyses, for example studies of genome-wide selection, mapping genetic variation to linguistic and demographic differences, and evaluating powerful approaches for trans-ethnic meta-analysis and fine-mapping. The first manuscript has been accepted for publication: Deepti Gurdasani , †, Tommy Carstensen1,2†, Fasil Tekola-Ayele †, Luca Pagani1†, Ioanna Tachmazidou1†, Konstantinos Hatzikotoulas1, Savita Karthikeyan1,2, Louise Iles1,2, Martin O. Pollard1, Ananyo Choudhury , Graham R. S. Ritchie1, , Yali Xue1, Jennifer Asimit1, Rebecca N. Nsubuga , Elizabeth H. Young1,2, Cristina Pomilla1,2, Katja Kivinen1, Kirk Rockett , Anatoli Kamali6, Ayo P. Doumatey3, Gershim Asiki6, Janet Seeley6, Fatoumatta Sisay-Joof , Muminatou Jallow8, Stephen Tollman4, , Ephrem Mekonnen , Rosemary Ekong , Tamiru Oljira10, Neil Bradman , Kalifa Bojang8, Michele Ramsay4, Adebowale Adeyemo3, Endashaw Bekele10, Ayesha Motala , Shane A. Norris4, Fraser Pirie13, Pontiano Kaleebu6, Dominic Kwiatkowski1, Chris Tyler-Smith1‡, Charles Rotimi3‡, Eleftheria Zeggini1‡ and Manjinder S. Sandhu1,2‡. (In press) The African Genome Variation Project shapes medical genetics in Africa. Nature
Start Year 2011
 
Description African Genome Variation (AGV) 
Organisation National Institutes of Health (NIH)
Department Centre for Research on Genomics and Global Health (CRGGH)
Country United States of America 
Sector Public 
PI Contribution This work aims to facilitate large-scale genetic association studies in diseases of relevance to SSA populations by providing first insights into the genetic variation landscape of different ethnic groups across SSA. My research team genotyped 100 unrelated individuals from each of several ethnic or ethno-linguistic groups on the 2.5 million SNP Illumina HumanOmni chip. To corroborate our analyses we also included whole genome sequences for three of these groups. This work will inform genomic epidemiological studies in SSA by providing a reference for allelic, haplotype and linkage disequilibrium (LD) structure for common variants in populations not covered by the HapMap project. This project has been designed to provide a currently unavailable genome-wide view of common variation and a framework for statistically imputing genetic variants for genome wide association studies in anticipation of future larger-scale whole-genome sequencing endeavours in relevant populations.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa provided existing (biobanked) sample collections with appropriate research ethics consent. Most of these partners were also directly involved in the analyses of the resulting data.
Impact The overarching aim of this project was to characterise common (minor allele frequency > 5 percent) sequence variation in SSA populations in order to facilitate the design of powerful genetic association studies. Specifically, we will aim to: 1) examine the allele frequency spectrum of variants on the chip; 2) characterise patterns of LD and haplotype structure; 3) evaluate optimal study designs for African genomics; 4) investigate imputation-based approaches aiming to increase genetic association study power; 5) identify analytical challenges and develop statistical genetics methods to address them; 6) generate a valuable resource for the scientific community; 7) promote collaboration and synergies among contributing parties; and 8) provide a research framework and resource for additional analyses, for example studies of genome-wide selection, mapping genetic variation to linguistic and demographic differences, and evaluating powerful approaches for trans-ethnic meta-analysis and fine-mapping. The first manuscript has been accepted for publication: Deepti Gurdasani , †, Tommy Carstensen1,2†, Fasil Tekola-Ayele †, Luca Pagani1†, Ioanna Tachmazidou1†, Konstantinos Hatzikotoulas1, Savita Karthikeyan1,2, Louise Iles1,2, Martin O. Pollard1, Ananyo Choudhury , Graham R. S. Ritchie1, , Yali Xue1, Jennifer Asimit1, Rebecca N. Nsubuga , Elizabeth H. Young1,2, Cristina Pomilla1,2, Katja Kivinen1, Kirk Rockett , Anatoli Kamali6, Ayo P. Doumatey3, Gershim Asiki6, Janet Seeley6, Fatoumatta Sisay-Joof , Muminatou Jallow8, Stephen Tollman4, , Ephrem Mekonnen , Rosemary Ekong , Tamiru Oljira10, Neil Bradman , Kalifa Bojang8, Michele Ramsay4, Adebowale Adeyemo3, Endashaw Bekele10, Ayesha Motala , Shane A. Norris4, Fraser Pirie13, Pontiano Kaleebu6, Dominic Kwiatkowski1, Chris Tyler-Smith1‡, Charles Rotimi3‡, Eleftheria Zeggini1‡ and Manjinder S. Sandhu1,2‡. (In press) The African Genome Variation Project shapes medical genetics in Africa. Nature
Start Year 2011
 
Description African Genome Variation (AGV) 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution This work aims to facilitate large-scale genetic association studies in diseases of relevance to SSA populations by providing first insights into the genetic variation landscape of different ethnic groups across SSA. My research team genotyped 100 unrelated individuals from each of several ethnic or ethno-linguistic groups on the 2.5 million SNP Illumina HumanOmni chip. To corroborate our analyses we also included whole genome sequences for three of these groups. This work will inform genomic epidemiological studies in SSA by providing a reference for allelic, haplotype and linkage disequilibrium (LD) structure for common variants in populations not covered by the HapMap project. This project has been designed to provide a currently unavailable genome-wide view of common variation and a framework for statistically imputing genetic variants for genome wide association studies in anticipation of future larger-scale whole-genome sequencing endeavours in relevant populations.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa provided existing (biobanked) sample collections with appropriate research ethics consent. Most of these partners were also directly involved in the analyses of the resulting data.
Impact The overarching aim of this project was to characterise common (minor allele frequency > 5 percent) sequence variation in SSA populations in order to facilitate the design of powerful genetic association studies. Specifically, we will aim to: 1) examine the allele frequency spectrum of variants on the chip; 2) characterise patterns of LD and haplotype structure; 3) evaluate optimal study designs for African genomics; 4) investigate imputation-based approaches aiming to increase genetic association study power; 5) identify analytical challenges and develop statistical genetics methods to address them; 6) generate a valuable resource for the scientific community; 7) promote collaboration and synergies among contributing parties; and 8) provide a research framework and resource for additional analyses, for example studies of genome-wide selection, mapping genetic variation to linguistic and demographic differences, and evaluating powerful approaches for trans-ethnic meta-analysis and fine-mapping. The first manuscript has been accepted for publication: Deepti Gurdasani , †, Tommy Carstensen1,2†, Fasil Tekola-Ayele †, Luca Pagani1†, Ioanna Tachmazidou1†, Konstantinos Hatzikotoulas1, Savita Karthikeyan1,2, Louise Iles1,2, Martin O. Pollard1, Ananyo Choudhury , Graham R. S. Ritchie1, , Yali Xue1, Jennifer Asimit1, Rebecca N. Nsubuga , Elizabeth H. Young1,2, Cristina Pomilla1,2, Katja Kivinen1, Kirk Rockett , Anatoli Kamali6, Ayo P. Doumatey3, Gershim Asiki6, Janet Seeley6, Fatoumatta Sisay-Joof , Muminatou Jallow8, Stephen Tollman4, , Ephrem Mekonnen , Rosemary Ekong , Tamiru Oljira10, Neil Bradman , Kalifa Bojang8, Michele Ramsay4, Adebowale Adeyemo3, Endashaw Bekele10, Ayesha Motala , Shane A. Norris4, Fraser Pirie13, Pontiano Kaleebu6, Dominic Kwiatkowski1, Chris Tyler-Smith1‡, Charles Rotimi3‡, Eleftheria Zeggini1‡ and Manjinder S. Sandhu1,2‡. (In press) The African Genome Variation Project shapes medical genetics in Africa. Nature
Start Year 2011
 
Description African Genome Variation (AGV) 
Organisation University of Cambridge
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution This work aims to facilitate large-scale genetic association studies in diseases of relevance to SSA populations by providing first insights into the genetic variation landscape of different ethnic groups across SSA. My research team genotyped 100 unrelated individuals from each of several ethnic or ethno-linguistic groups on the 2.5 million SNP Illumina HumanOmni chip. To corroborate our analyses we also included whole genome sequences for three of these groups. This work will inform genomic epidemiological studies in SSA by providing a reference for allelic, haplotype and linkage disequilibrium (LD) structure for common variants in populations not covered by the HapMap project. This project has been designed to provide a currently unavailable genome-wide view of common variation and a framework for statistically imputing genetic variants for genome wide association studies in anticipation of future larger-scale whole-genome sequencing endeavours in relevant populations.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa provided existing (biobanked) sample collections with appropriate research ethics consent. Most of these partners were also directly involved in the analyses of the resulting data.
Impact The overarching aim of this project was to characterise common (minor allele frequency > 5 percent) sequence variation in SSA populations in order to facilitate the design of powerful genetic association studies. Specifically, we will aim to: 1) examine the allele frequency spectrum of variants on the chip; 2) characterise patterns of LD and haplotype structure; 3) evaluate optimal study designs for African genomics; 4) investigate imputation-based approaches aiming to increase genetic association study power; 5) identify analytical challenges and develop statistical genetics methods to address them; 6) generate a valuable resource for the scientific community; 7) promote collaboration and synergies among contributing parties; and 8) provide a research framework and resource for additional analyses, for example studies of genome-wide selection, mapping genetic variation to linguistic and demographic differences, and evaluating powerful approaches for trans-ethnic meta-analysis and fine-mapping. The first manuscript has been accepted for publication: Deepti Gurdasani , †, Tommy Carstensen1,2†, Fasil Tekola-Ayele †, Luca Pagani1†, Ioanna Tachmazidou1†, Konstantinos Hatzikotoulas1, Savita Karthikeyan1,2, Louise Iles1,2, Martin O. Pollard1, Ananyo Choudhury , Graham R. S. Ritchie1, , Yali Xue1, Jennifer Asimit1, Rebecca N. Nsubuga , Elizabeth H. Young1,2, Cristina Pomilla1,2, Katja Kivinen1, Kirk Rockett , Anatoli Kamali6, Ayo P. Doumatey3, Gershim Asiki6, Janet Seeley6, Fatoumatta Sisay-Joof , Muminatou Jallow8, Stephen Tollman4, , Ephrem Mekonnen , Rosemary Ekong , Tamiru Oljira10, Neil Bradman , Kalifa Bojang8, Michele Ramsay4, Adebowale Adeyemo3, Endashaw Bekele10, Ayesha Motala , Shane A. Norris4, Fraser Pirie13, Pontiano Kaleebu6, Dominic Kwiatkowski1, Chris Tyler-Smith1‡, Charles Rotimi3‡, Eleftheria Zeggini1‡ and Manjinder S. Sandhu1,2‡. (In press) The African Genome Variation Project shapes medical genetics in Africa. Nature
Start Year 2011
 
Description African Genome Variation (AGV) 
Organisation University of KwaZulu-Natal
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution This work aims to facilitate large-scale genetic association studies in diseases of relevance to SSA populations by providing first insights into the genetic variation landscape of different ethnic groups across SSA. My research team genotyped 100 unrelated individuals from each of several ethnic or ethno-linguistic groups on the 2.5 million SNP Illumina HumanOmni chip. To corroborate our analyses we also included whole genome sequences for three of these groups. This work will inform genomic epidemiological studies in SSA by providing a reference for allelic, haplotype and linkage disequilibrium (LD) structure for common variants in populations not covered by the HapMap project. This project has been designed to provide a currently unavailable genome-wide view of common variation and a framework for statistically imputing genetic variants for genome wide association studies in anticipation of future larger-scale whole-genome sequencing endeavours in relevant populations.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa provided existing (biobanked) sample collections with appropriate research ethics consent. Most of these partners were also directly involved in the analyses of the resulting data.
Impact The overarching aim of this project was to characterise common (minor allele frequency > 5 percent) sequence variation in SSA populations in order to facilitate the design of powerful genetic association studies. Specifically, we will aim to: 1) examine the allele frequency spectrum of variants on the chip; 2) characterise patterns of LD and haplotype structure; 3) evaluate optimal study designs for African genomics; 4) investigate imputation-based approaches aiming to increase genetic association study power; 5) identify analytical challenges and develop statistical genetics methods to address them; 6) generate a valuable resource for the scientific community; 7) promote collaboration and synergies among contributing parties; and 8) provide a research framework and resource for additional analyses, for example studies of genome-wide selection, mapping genetic variation to linguistic and demographic differences, and evaluating powerful approaches for trans-ethnic meta-analysis and fine-mapping. The first manuscript has been accepted for publication: Deepti Gurdasani , †, Tommy Carstensen1,2†, Fasil Tekola-Ayele †, Luca Pagani1†, Ioanna Tachmazidou1†, Konstantinos Hatzikotoulas1, Savita Karthikeyan1,2, Louise Iles1,2, Martin O. Pollard1, Ananyo Choudhury , Graham R. S. Ritchie1, , Yali Xue1, Jennifer Asimit1, Rebecca N. Nsubuga , Elizabeth H. Young1,2, Cristina Pomilla1,2, Katja Kivinen1, Kirk Rockett , Anatoli Kamali6, Ayo P. Doumatey3, Gershim Asiki6, Janet Seeley6, Fatoumatta Sisay-Joof , Muminatou Jallow8, Stephen Tollman4, , Ephrem Mekonnen , Rosemary Ekong , Tamiru Oljira10, Neil Bradman , Kalifa Bojang8, Michele Ramsay4, Adebowale Adeyemo3, Endashaw Bekele10, Ayesha Motala , Shane A. Norris4, Fraser Pirie13, Pontiano Kaleebu6, Dominic Kwiatkowski1, Chris Tyler-Smith1‡, Charles Rotimi3‡, Eleftheria Zeggini1‡ and Manjinder S. Sandhu1,2‡. (In press) The African Genome Variation Project shapes medical genetics in Africa. Nature
Start Year 2011
 
Description African Genome Variation (AGV) 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution This work aims to facilitate large-scale genetic association studies in diseases of relevance to SSA populations by providing first insights into the genetic variation landscape of different ethnic groups across SSA. My research team genotyped 100 unrelated individuals from each of several ethnic or ethno-linguistic groups on the 2.5 million SNP Illumina HumanOmni chip. To corroborate our analyses we also included whole genome sequences for three of these groups. This work will inform genomic epidemiological studies in SSA by providing a reference for allelic, haplotype and linkage disequilibrium (LD) structure for common variants in populations not covered by the HapMap project. This project has been designed to provide a currently unavailable genome-wide view of common variation and a framework for statistically imputing genetic variants for genome wide association studies in anticipation of future larger-scale whole-genome sequencing endeavours in relevant populations.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa provided existing (biobanked) sample collections with appropriate research ethics consent. Most of these partners were also directly involved in the analyses of the resulting data.
Impact The overarching aim of this project was to characterise common (minor allele frequency > 5 percent) sequence variation in SSA populations in order to facilitate the design of powerful genetic association studies. Specifically, we will aim to: 1) examine the allele frequency spectrum of variants on the chip; 2) characterise patterns of LD and haplotype structure; 3) evaluate optimal study designs for African genomics; 4) investigate imputation-based approaches aiming to increase genetic association study power; 5) identify analytical challenges and develop statistical genetics methods to address them; 6) generate a valuable resource for the scientific community; 7) promote collaboration and synergies among contributing parties; and 8) provide a research framework and resource for additional analyses, for example studies of genome-wide selection, mapping genetic variation to linguistic and demographic differences, and evaluating powerful approaches for trans-ethnic meta-analysis and fine-mapping. The first manuscript has been accepted for publication: Deepti Gurdasani , †, Tommy Carstensen1,2†, Fasil Tekola-Ayele †, Luca Pagani1†, Ioanna Tachmazidou1†, Konstantinos Hatzikotoulas1, Savita Karthikeyan1,2, Louise Iles1,2, Martin O. Pollard1, Ananyo Choudhury , Graham R. S. Ritchie1, , Yali Xue1, Jennifer Asimit1, Rebecca N. Nsubuga , Elizabeth H. Young1,2, Cristina Pomilla1,2, Katja Kivinen1, Kirk Rockett , Anatoli Kamali6, Ayo P. Doumatey3, Gershim Asiki6, Janet Seeley6, Fatoumatta Sisay-Joof , Muminatou Jallow8, Stephen Tollman4, , Ephrem Mekonnen , Rosemary Ekong , Tamiru Oljira10, Neil Bradman , Kalifa Bojang8, Michele Ramsay4, Adebowale Adeyemo3, Endashaw Bekele10, Ayesha Motala , Shane A. Norris4, Fraser Pirie13, Pontiano Kaleebu6, Dominic Kwiatkowski1, Chris Tyler-Smith1‡, Charles Rotimi3‡, Eleftheria Zeggini1‡ and Manjinder S. Sandhu1,2‡. (In press) The African Genome Variation Project shapes medical genetics in Africa. Nature
Start Year 2011
 
Description African Genome Variation (AGV) 
Organisation University of the Witwatersrand
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution This work aims to facilitate large-scale genetic association studies in diseases of relevance to SSA populations by providing first insights into the genetic variation landscape of different ethnic groups across SSA. My research team genotyped 100 unrelated individuals from each of several ethnic or ethno-linguistic groups on the 2.5 million SNP Illumina HumanOmni chip. To corroborate our analyses we also included whole genome sequences for three of these groups. This work will inform genomic epidemiological studies in SSA by providing a reference for allelic, haplotype and linkage disequilibrium (LD) structure for common variants in populations not covered by the HapMap project. This project has been designed to provide a currently unavailable genome-wide view of common variation and a framework for statistically imputing genetic variants for genome wide association studies in anticipation of future larger-scale whole-genome sequencing endeavours in relevant populations.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa provided existing (biobanked) sample collections with appropriate research ethics consent. Most of these partners were also directly involved in the analyses of the resulting data.
Impact The overarching aim of this project was to characterise common (minor allele frequency > 5 percent) sequence variation in SSA populations in order to facilitate the design of powerful genetic association studies. Specifically, we will aim to: 1) examine the allele frequency spectrum of variants on the chip; 2) characterise patterns of LD and haplotype structure; 3) evaluate optimal study designs for African genomics; 4) investigate imputation-based approaches aiming to increase genetic association study power; 5) identify analytical challenges and develop statistical genetics methods to address them; 6) generate a valuable resource for the scientific community; 7) promote collaboration and synergies among contributing parties; and 8) provide a research framework and resource for additional analyses, for example studies of genome-wide selection, mapping genetic variation to linguistic and demographic differences, and evaluating powerful approaches for trans-ethnic meta-analysis and fine-mapping. The first manuscript has been accepted for publication: Deepti Gurdasani , †, Tommy Carstensen1,2†, Fasil Tekola-Ayele †, Luca Pagani1†, Ioanna Tachmazidou1†, Konstantinos Hatzikotoulas1, Savita Karthikeyan1,2, Louise Iles1,2, Martin O. Pollard1, Ananyo Choudhury , Graham R. S. Ritchie1, , Yali Xue1, Jennifer Asimit1, Rebecca N. Nsubuga , Elizabeth H. Young1,2, Cristina Pomilla1,2, Katja Kivinen1, Kirk Rockett , Anatoli Kamali6, Ayo P. Doumatey3, Gershim Asiki6, Janet Seeley6, Fatoumatta Sisay-Joof , Muminatou Jallow8, Stephen Tollman4, , Ephrem Mekonnen , Rosemary Ekong , Tamiru Oljira10, Neil Bradman , Kalifa Bojang8, Michele Ramsay4, Adebowale Adeyemo3, Endashaw Bekele10, Ayesha Motala , Shane A. Norris4, Fraser Pirie13, Pontiano Kaleebu6, Dominic Kwiatkowski1, Chris Tyler-Smith1‡, Charles Rotimi3‡, Eleftheria Zeggini1‡ and Manjinder S. Sandhu1,2‡. (In press) The African Genome Variation Project shapes medical genetics in Africa. Nature
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation Makerere University College of Health Sciences
Country Uganda, Republic of 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation Medical Research Council (MRC)
Department MRC Centre for Genomics and Global Health
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation Medical Research Council (MRC)
Department MRC Unit, The Gambia
Country Gambia, Republic of the 
Sector Public 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation Medical Research Council (MRC)
Department Medical Research Council (MRC), MRC/UVRI Unit, Uganda
Country Uganda, Republic of 
Sector Public 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation Moi University
Department School of Medicine
Country Kenya, Republic of 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation National Human Genome Center; Howard University
Country United States of America 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation National Institute for Medical Research, Tanzania
Department Mwanza Intervention Trials Unit (MITU)
Country Tanzania, United Republic of 
Sector Public 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation National Institutes of Health (NIH)
Department National Human Genome Research Institute (NHGRI)
Country United States of America 
Sector Public 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of Cambridge
Department MRC Epidemiology Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Multiple 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of Cape Town
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of Conakry
Country Guinea, Republic of 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of Ghana
Department School of Medicine
Country Ghana, Republic of 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of Ibadan
Country Nigeria, Federal Republic of 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of KwaZulu-Natal
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of Nigeria
Department University of Nigeria Teaching Hospital (UNTH) Ituku/Ozalla Enugu
Country Nigeria, Federal Republic of 
Sector Hospitals 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of Oxford
Department Wellcome Trust Centre for Human Genetics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of Yaoundé
Country Cameroon, Republic of 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of the Gambia
Country Gambia, Republic of the 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation University of the Witwatersrand
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description African Partnership for Chronic Disease Research 
Organisation Wellcome Trust
Department Malawi-Liverpool Wellcome Trust Clinical Research Programme
Country Malawi, Republic of 
Sector Charity/Non Profit 
PI Contribution 1. Set-up and coordination of the partnership. 2. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 3. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 18 centres from 12 different countries. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, bioethics, population-based surveys and interventions. African centres also contribute existing resources and infostructure for sample collection (clinics and field stations) and analyses.
Impact Two successful grant application have resulted so far from this partnership: Wellcome Trust (WT099316MA) Burden, spectrum and aetiology of type 2 diabetes in sub-Saharan Africa 2013-2018 £2,550,000 MRC Research partnership to assess the burden and aetiology of non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) 2013-2018 £885,314 The partnership is also taking part in several ongoing projects including the African Genome Variation project, led by the Wellcome Trust sanger Institute, and a HIV/ART/NCD meta-analysis.
Start Year 2011
 
Description EuroCoord Network of Excellence 
Organisation Amsterdam Cohort Study Among Homosexual Men
Country Netherlands, Kingdom of the 
Sector Private 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation Austrian HIV Cohort Study (AHIVCOS)
Country Austria, Republic of 
Sector Academic/University 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation Cohort of RIS (CoRIS)
Country Spain, Kingdom of 
Sector Hospitals 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation German HIV-1 Seroconverter Cohort
Country Germany, Federal Republic of 
Sector Charity/Non Profit 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation InfCare Swedish Cohort
Country Sweden, Kingdom of 
Sector Academic/University 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation International AIDS Vaccine Initiative (IAVI)
Country Global 
Sector Charity/Non Profit 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation Italian Cohort of Antiretroviral Naïve Patients (ICONA)
Country Italy, Italian Republic 
Sector Charity/Non Profit 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation Lyon Primary Infection Cohort (LPIC)
Country France, French Republic 
Sector Charity/Non Profit 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation PHAEDRA, Sydney AIDS Prospective Study and Sydney Primary HIV Infection Cohort
Country Australia, Commonwealth of 
Sector Academic/University 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation Primary Infection Cohort (PRIMO)
Country France, French Republic 
Sector Academic/University 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation Southern Alberta Clinic (SAC)
Country Canada 
Sector Hospitals 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation St-Pierre, Belgium (COHERE)
Country Belgium, Kingdom of 
Sector Academic/University 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation UK Register of HIV Seroconverters (UKRHS)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description EuroCoord Network of Excellence 
Organisation University of Athens
Department Athens Multicentre AIDS Cohort Study (AMACS)
Country Greece, Hellenic Republic 
Sector Academic/University 
PI Contribution EuroCoord (funded by EC FP7) is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. My team is leading the project 'Genomic Studies of HIV Control in the CASCADE Collaboration', which is part of one of EuroCoord workpackages. The aim of this project is to examine the genetic differences contributing to viral and disease control in HIV infection, by identifying rare host and virus genetic variants in individuals at the two extremes of the immunological and clinical spectrum. Specifically we will sequence exomes from 200 individuals: roughly 100 individuals belonging to the 'elite-LTNP' group and 100 individuals from the 'rapid progression' group.
Collaborator Contribution EuroCoord partners are grouped into: - Founding networks - Beneficiaries - Third parties We are part of the 'beneficiaries'. Listed above are the cohort studies, part of the 'founding networks', which are contributing to our project. The project use existing data and existing samples (blood and DNA) previously collected as part of the HIV cohort studies. The patner cohort studies identified eligible participants from study records at the originating study sites and provided samples and data.
Impact We have already collated most samples for the project and analyses are underway.
Start Year 2012
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Addis Ababa University
Country Ethiopia, Federal Democratic Republic of 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Aix-Marseille University
Country France, French Republic 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Armauer Hansen Research Institute (AHRI)
Country Ethiopia, Federal Democratic Republic of 
Sector Charity/Non Profit 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Corporate Policy Unit
Country South Africa, Republic of 
Sector Public 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Henry Stewart Conferences and Events
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Institute of Development Research (IRD)
Department IRD Centre de Montpelier
Country France, French Republic 
Sector Charity/Non Profit 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Institute of Development Research (IRD)
Country France, French Republic 
Sector Public 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation International Centre for Research and Development of Livestock in Subhumid (CIRDES)
Country Burkina Faso 
Sector Public 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Lebanese American University
Country Lebanon, Lebanese Republic 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Loyola University Medical Center
Country United States of America 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation MENTOR Initiative
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation MRC/UVRI Uganda Research Unit on AIDS
Country Uganda, Republic of 
Sector Public 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Makerere University
Country Uganda, Republic of 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation National Centre for Research and Training on Malaria (CNRFP)
Country Burkina Faso 
Sector Public 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation National Institutes of Health (NIH)
Department Centre for Research on Genomics and Global Health (CRGGH)
Country United States of America 
Sector Public 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Pasteur Institute, Algiers
Country Algeria, People's Democratic Republic of 
Sector Public 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation Stony Brook University
Country United States of America 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University College London
Department School of Life and Medical Sciences
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Bamako
Country Mali, Republic of 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Buea
Country Cameroon, Republic of 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Cape Town
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Geneva
Country Switzerland, Swiss Confederation 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Glasgow
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of KwaZulu-Natal
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Lausanne
Country Switzerland, Swiss Confederation 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Liverpool
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Maryland
Department Centre for Vaccine Development (CVD)
Country United States of America 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Maryland
Country United States of America 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Stellenbosch
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Stellenbosch
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Sussex
Department Brighton and Sussex Medical School
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation University of Yaoundé
Country Cameroon, Republic of 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description Genetic Diversity in Africa Project (GDAP) 
Organisation VU University Medical Center
Country Netherlands, Kingdom of the 
Sector Academic/University 
PI Contribution Globally, human populations show structured genetic diversity as a result of geographical dispersion, selection and drift. Understanding this genetic variation can provide insights into our human origins and the evolutionary processes that shape both human adaptation and variation in disease.[1 2] In these contexts, Africa represents the ancestral birthplace of modern humans.[3] Populations from Africa have the highest levels of genetic diversity.[4 5] This characteristic, in addition to historical genetic admixture, can lead to complexities in the design of studies assessing the genetic determinants of disease and human variation. However, such studies of African populations are also likely to provide new opportunities to discover novel disease susceptibility loci and variants and refine gene-disease association signals.[3] A systematic assessment of genetic diversity within Africa would facilitate genomic epidemiological studies in the region. The Genome Diversity in Africa Project (GDAP) will importantly extend previous efforts to characterise population genetic diversity in Africa-informing population history and movement, evolutionary adaptation and disease susceptibility across Africa. Importantly, the GDAP will also help develop local resources and research capacity for public health and genomic epidemiological research, including approaches to strengthen research capacity, training, and collaboration across the region. Using a sequencing-based approach, GDAP aims to significantly advance the comprehensive catalogue of human genetic variation in Africa started by the African Genome Variation (AGV) project (African Genome Variation), including single nucleotide polymorphisms (SNPs), structural variants, and haplotypes. My research team will sequence at low and high depth the whole genome of around 100 individuals from each ethnolinguistic group, and complement these data with 2.5M Illumina array data from distinct regions within Africa. In total, we will aim to sequence up to 2,000 genomes. This resource will extend our understanding of our human origins, population history, and patterns of genetic diversity within and among populations in Africa. Furthermore, it will provide a global resource to help design, implement and interpret genomic studies in Africa populations and studies comprising globally diverse populations, thus complementing existing genomic resources.
Collaborator Contribution Research groups and institutions, other consortia, and health organisations working in the fields of population health, health service provision, and genomics in Africa will provide existing (biobanked) or new sample collections with appropriate research ethics consent. Some of these partners will be also directly involved in the analyses of the resulting data.
Impact This is a recent collaboration and there is no tangible putput yet however our scientific objectives are to: 1) develop a resource that provides a comprehensive catalogue of genetic variation in populations from Africa accessible to the global scientific community; 2) characterise population genetic diversity, structure, gene flow and admixture across Africa; 3) develop a cost-efficient, next-generation genotype array for diverse populations across Africa; 4) facilitate whole genome-sequencing association studies of complex traits and diseases by developing a reference panel for imputation and resource for enhancing fine-mapping disease susceptibility loci. These scientific objectives will be supported by cross-cutting operational activities, including network and management of the consortium, research ethics, and research capacity building in statistical genetics and bioinformatics.
Start Year 2013
 
Description H3A Diabetes 
Organisation Institute of Human Virology
Country Nigeria, Federal Republic of 
Sector Charity/Non Profit 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation MRC/UVRI Uganda Research Unit on AIDS
Country Uganda, Republic of 
Sector Public 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation National Institute for Medical Research, Tanzania
Department Mwanza Intervention Trials Unit (MITU)
Country Tanzania, United Republic of 
Sector Public 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation National Institutes of Health (NIH)
Department National Human Genome Research Institute (NHGRI)
Country United States of America 
Sector Public 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation Newcastle University
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation University of Cape Town
Department Division of Endocrinology and Diabetic Medicine
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation University of Ghana
Department School of Medicine
Country Ghana, Republic of 
Sector Academic/University 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation University of KwaZulu-Natal
Department Department of Diabetes and Endocrinology
Country South Africa, Republic of 
Sector Academic/University 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation University of Malawi
Department College of Medicine
Country Malawi, Republic of 
Sector Academic/University 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation University of Yaoundé
Country Cameroon, Republic of 
Sector Academic/University 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description H3A Diabetes 
Organisation Wellcome Trust
Department Malawi-Liverpool Wellcome Trust Clinical Research Programme
Country Malawi, Republic of 
Sector Charity/Non Profit 
PI Contribution 1. Expertise and research capacity in: genetics/genomics of chronic disease, informatics, large-scale analytical pipelines, statistical genetics, epidemiology and public health. 2. Access to high throughput next-generation sequencing and genotyping laboratory and analytical pipelines and infrastructure.
Collaborator Contribution The partnership includes 10 centres directly and 16 centres in total. Expertises range from epidemiology of diabetes and cardiovascular diseases in African populations to population genetics/genomics, population-based surveys and interventions. African centres also contribute existing resources and infrastructure for sample collection (clinics and field stations) and analyses. On 2015, H3A has contributed together with APCDR to fund PhD Scholarships and postdoctoral fellowships.
Impact This partnership is still in its early stages. The general aim of the partnership is conduct a multi-centre population based cross-sectional survey-assessing the distribution and prevalence of a range of risk factors and quantitative phenotypes. We are currently working together to finalise the common study protocol and geographical sampling frame that will be used by all centres, enabling data from each site to combined with data from other centres for analysis. This study design provides a research framework that will allow opportunities to: 1) conduct a detailed examination of T2D and its complications; 2) assess the risk factors associated with T2D and its complications, including environmental, behavioural, infectious and genetic risk factors; 3) examine the population distribution of these risk factors; 4) harness genomic technologies to understand the aetiology of T2D and its complications in SSA; 5) provide a platform for longer-term longitudinal studies of disease incidence; and 6) develop a sustainable resource to align case series of other diseases and traits to the cross-sectional surveys. In 2015, 3x PhD studentships and 1x postdoctoral fellowship were awarded including fees, stipends and research costs.
Start Year 2012
 
Description HIV Genomics Consortium (HGC) 
Organisation Academy of Medical Sciences (AMS)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Barts Health NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Cambridge University Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Central and North West London NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Charing Cross Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Chelsea and Westminster Hospital NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation East and North Hertfordshire NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Homerton University Hospital NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation King's College London
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation MRC/UVRI Uganda Research Unit on AIDS
Country Uganda, Republic of 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Medical Research Council (MRC)
Department MRC Clinical Trials Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Medical Research Council (MRC)
Department MRC Human Immunology Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation National Institutes of Health (NIH)
Department National Institute of General Medical Sciences (NIGMS)
Country United States of America 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Portsmouth Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Royal Cornwall Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation Sheffield Teaching Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation St George's Healthcare NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation St Mary's Hospital, London
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation St Richard's Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation St Thomas' Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation University College London Hospital
Department University College London Hospitals Charity (UCLH)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation University of Cambridge
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation University of Oxford
Department Wellcome Trust Centre for Human Genetics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HIV Genomics Consortium (HGC) 
Organisation West Hertfordshire Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution My research team has started the collaboration and has designed, coordinated and delivered the 'The HIV Exome Sequencing Study: A pilot study of the genetic determinants of elite control in HIV infection'.
Collaborator Contribution For 'The HIV Exome Sequencing Study' collaborating clinics identified and recruited eligible participants, collected blood samples and extracted relevant clinical data. Other partners contributed to the design of the study.
Impact The specific objectives of 'The HIV Exome Sequencing Study' were as follows: 1. To conduct a pilot study to identify host and viral genetic variants that contribute to control of HIV infection. 2. To develop a research framework for large scale studies in HIV genomics. 3. To replicate findings from the study within the proposed collaboration. 4. To use fine mapping techniques to identify causal variants. 5. To develop a generic research framework to study genetic determinants of other infectious diseases. This pilot study has been completed and the data are being analysed in the context of other larger collaborations (HIV Eurocord, International HIV Acquisition Consortium (IHAC)). Other outputs of the HGC to date have been the following manuscripts: A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719
Start Year 2010
 
Description HLA Genomics Resource 
Organisation University of Oxford
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution we aim to bring together groups of individuals who have worked on HLA from a genomic or immunological perspective for many years, or who have experience in inferring structure or diversity within complex regions of the genome using multiple genotyping or sequencing platforms. The overarching vision of the Consortium is to integrate as many existing datasets as possible relevant to HLA ensuring appropriate curation and description of the data, to thus enable a comprehensive description of the structure and diversity of the region. We anticipate that the activities resulting from this work will create a resource that can be applied to ongoing and future initiatives to understand the relationship and mechanisms behind HLA associations with disease that will hopefully lead to long-awaited translational discoveries that will lead to improvements in human health. GOALS 1. To centralise the secure deposition of a range of reference datasets relevant to HLA. 2. To describe the structure and diversity of the extended HLA region across multiple populations (including HLA and non-HLA genes) and make this information available to researchers worldwide. 3. To develop standardised pipelines for mapping and calling variants and alleles using datasets derived from diverse platforms centred on HLA. 4. To develop and make available software to infer and/or impute high-resolution HLA types from a variety of data sources and populations. 5. To develop an interactive portal to enable researchers to share data, resources and information relevant to HLA and to access the findings from this Consortium effort.
Collaborator Contribution 1. To centralise the secure deposition of a range of reference datasets relevant to HLA. 2. To describe the structure and diversity of the extended HLA region across multiple populations (including HLA and non-HLA genes) and make this information available to researchers worldwide. 3. To develop standardised pipelines for mapping and calling variants and alleles using datasets derived from diverse platforms centred on HLA. 4. To develop and make available software to infer and/or impute high-resolution HLA types from a variety of data sources and populations. 5. To develop an interactive portal to enable researchers to share data, resources and information relevant to HLA and to access the findings from this Consortium effort.
Impact The first step towards achieving the ambitious goals of this Consortium effort is to identify as many datasets relevant to this initiative as possible. The collation of data from samples from multiple diverse populations will be prioritised but may include that of a variety of formats such as: genotype, classical-based typing, or exome or whole-genome based information. In some cases, original biological samples may be accessible that may be used for novel data generation to guide consistency in methodology. Data sharing agreements will be put in place for all datasets as necessary to ensure that data is shared in a responsible way.
Start Year 2016
 
Description Lp(a) levels in a population from sub-Saharan Africa 
Organisation MRC/UVRI Uganda Research Unit on AIDS
Country Uganda, Republic of 
Sector Public 
PI Contribution Together with MRC/UVRI, and with independent MRC grant funding we have devised and conducted a large scale study in Uganda--assessing the distribution of cardiometabolic risk factors. Within context of the current MRC grant funding, we aim to examine the distribution of Lp(a) and other risk factors for heart disease in this population.
Collaborator Contribution One of our primary research mandates for the current grant was to the characterise the correlates of Lp(a) levels in different populations using standardised measurements (Objective 1). We originally focused on populations of European and South Asian descent. This collaboration allowed us to extend these studies to populations from sub-Saharan Africa. Importantly, it has been suggested that elevated levels of lipoprotein(a) [Lp(a)] are a risk marker for coronary heart disease in European populations, but not among African Americans. This is despite the observation that African American populatons have both higher Lp(a) levels and higher absolute cardiovascular event rates. There is a paucity of such data in populations from Africa, where the varying genetic background may alter the association between the cognate gene and Lp(a) levels. We aim to compare data across European, Souh Asian and African populations.
Impact We now have data on more than 8,000 study participants from Uganda, which will be compared with data from 20,000 Europeans and 20,000 South Asians. This is a multi-disciplinary collaboration involving clinicians, epidemiologists and geneticists.
Start Year 2010
 
Description Wellcome Trust Sanger Faculty 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution We have developed a large scale resource to study the aetiology of cardiometabolic traits and diseases in up to 8,000 participants from sub-Saharan Africa.
Collaborator Contribution Access to analytical pipelines and sequencing anf genotyping pipelines for genomic studies. Also, provide key training for members of the team, as well as administrative, informatic and data management support for APCDR activities.
Impact Genomic data on 5,000 individuals and whole genome sequencing data on 100 participants. These data will be available to the scientific community through a managed access system. APCDR data is currently handled by the Wellcome Trust Sanger Institute. Other APCDR resources such as the web site, have also been integrated within this collaborative agreement.
Start Year 2010
 
Title Hyperthension and use of salt substitutes, Uganda 
Description We are currently drafting the protocol for an intervention that would pilot the use of a salt substitute in participants with high blood pressure selected from the Uganda General Population Cohort Study. The initial pilots are funded through MRC support. 
Type Preventative Intervention - Nutrition and Chemoprevention
Current Stage Of Development Initial development
Year Development Stage Completed 2012
Development Status Under active development/distribution
Impact No measurable impact yet. 
 
Description Engaging with local communities 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact Presentations to research groups, field teams and local community leaders (around twenty participants).

The engagement activities facilitated the planned study, helping increase local in the study.
Year(s) Of Engagement Activity 2010